Literature DB >> 24664660

Genetic epilepsy syndromes without structural brain abnormalities: clinical features and experimental models.

Renzo Guerrini1, Carla Marini, Massimo Mantegazza.   

Abstract

Research in genetics of epilepsy represents an area of great interest both for clinical purposes and for understanding the basic mechanisms of epilepsy. Most mutations in epilepsies without structural brain abnormalities have been identified in ion channel genes, but an increasing number of genes involved in a diversity of functional and developmental processes are being recognized through whole exome or genome sequencing. Targeted molecular diagnosis is now available for different forms of epilepsy. The identification of epileptogenic mutations in patients before epilepsy onset and the possibility of developing therapeutic strategies tested in experimental models may facilitate experimental approaches that prevent epilepsy or decrease its severity. Functional analysis is essential for better understanding pathogenic mechanisms and gene interactions. In vitro experimental systems are either cells that usually do not express the protein of interest or neurons in primary cultures. In vivo/ex vivo systems are organisms or preparations obtained from them (e.g., brain slices), which should better model the complexity of brain circuits and actual pathophysiological conditions. Neurons differentiated from induced pluripotent stem cells generated from the skin fibroblasts of patients have recently allowed the study of mutations in human neurons having the genetic background of a given patient. However, there is remarkable complexity underlying epileptogenesis in the clinical dimension, as reflected by the fact that experimental models have not provided yet results having clinical translation and that, with a few exceptions concerning rare conditions, no new curative treatment has emerged from any genetic finding in epilepsy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24664660      PMCID: PMC3996114          DOI: 10.1007/s13311-014-0267-0

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  170 in total

1.  Mosaic SCN1A mutation in familial severe myoclonic epilepsy of infancy.

Authors:  Carla Marini; Davide Mei; J Helen Cross; Renzo Guerrini
Journal:  Epilepsia       Date:  2006-10       Impact factor: 5.864

2.  Localization of a gene for partial epilepsy to chromosome 10q.

Authors:  R Ottman; N Risch; W A Hauser; T A Pedley; J H Lee; C Barker-Cummings; A Lustenberger; K J Nagle; K S Lee; M L Scheuer
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

3.  Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder.

Authors:  I E Scheffer; K P Bhatia; I Lopes-Cendes; D R Fish; C D Marsden; E Andermann; F Andermann; R Desbiens; D Keene; F Cendes
Journal:  Brain       Date:  1995-02       Impact factor: 13.501

Review 4.  Channelopathies in idiopathic epilepsy.

Authors:  Sarah E Heron; Ingrid E Scheffer; Samuel F Berkovic; Leanne M Dibbens; John C Mulley
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

5.  Nicotine-induced dystonic arousal complex in a mouse line harboring a human autosomal-dominant nocturnal frontal lobe epilepsy mutation.

Authors:  Yaroslav Teper; Douglas Whyte; Elizabeth Cahir; Henry A Lester; Sharon R Grady; Michael J Marks; Bruce N Cohen; Carlos Fonck; Tristan McClure-Begley; J Michael McIntosh; Cesar Labarca; Andrew Lawrence; Feng Chen; Ilse Gantois; Philip J Davies; Steven Petrou; Mark Murphy; John Waddington; Malcolm K Horne; Samuel F Berkovic; John Drago
Journal:  J Neurosci       Date:  2007-09-19       Impact factor: 6.167

Review 6.  The role of the nicotinic acetylcholine receptors in sleep-related epilepsy.

Authors:  Carla Marini; Renzo Guerrini
Journal:  Biochem Pharmacol       Date:  2007-06-23       Impact factor: 5.858

7.  Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus.

Authors:  R Guerrini; F Moro; M Kato; A J Barkovich; T Shiihara; M A McShane; J Hurst; M Loi; J Tohyama; V Norci; K Hayasaka; U J Kang; S Das; W B Dobyns
Journal:  Neurology       Date:  2007-07-31       Impact factor: 9.910

8.  A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome).

Authors:  Mitsuhiro Kato; Shinji Saitoh; Atsushi Kamei; Hideaki Shiraishi; Yuki Ueda; Manami Akasaka; Jun Tohyama; Noriyuki Akasaka; Kiyoshi Hayasaka
Journal:  Am J Hum Genet       Date:  2007-06-11       Impact factor: 11.025

9.  Idiopathic epilepsies with seizures precipitated by fever and SCN1A abnormalities.

Authors:  Carla Marini; Davide Mei; Teresa Temudo; Anna Rita Ferrari; Daniela Buti; Charlotte Dravet; Ana I Dias; Ana Moreira; Eulalia Calado; Stefano Seri; Brian Neville; Juan Narbona; Evan Reid; Roberto Michelucci; Federico Sicca; Helen J Cross; Renzo Guerrini
Journal:  Epilepsia       Date:  2007-06-11       Impact factor: 5.864

10.  The spectrum of SCN1A-related infantile epileptic encephalopathies.

Authors:  Louise A Harkin; Jacinta M McMahon; Xenia Iona; Leanne Dibbens; James T Pelekanos; Sameer M Zuberi; Lynette G Sadleir; Eva Andermann; Deepak Gill; Kevin Farrell; Mary Connolly; Thorsten Stanley; Michael Harbord; Frederick Andermann; Jing Wang; Sat Dev Batish; Jeffrey G Jones; William K Seltzer; Alison Gardner; Grant Sutherland; Samuel F Berkovic; John C Mulley; Ingrid E Scheffer
Journal:  Brain       Date:  2007-03       Impact factor: 13.501

View more
  15 in total

1.  Analysis of catechol-O-methyltransferase gene mutation and identification of new pathogenic gene for paroxysmal kinesigenic dyskinesia.

Authors:  Chengzhi Gu; Jia Li; Lianhai Zhu; Zhenhui Lu; Huaiyu Huang
Journal:  Neurol Sci       Date:  2015-12-09       Impact factor: 3.307

2.  Novel concepts in epileptogenesis and its prevention.

Authors:  Lara E Jehi; Annamaria Vezzani
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

3.  Modeling cortical spreading depression induced by the hyperactivity of interneurons.

Authors:  Mathieu Desroches; Olivier Faugeras; Martin Krupa; Massimo Mantegazza
Journal:  J Comput Neurosci       Date:  2019-10-17       Impact factor: 1.621

Review 4.  Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.

Authors:  Wolfgang Löscher
Journal:  Neurochem Res       Date:  2017-03-13       Impact factor: 3.996

5.  Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations.

Authors:  Valentina Cetica; Sara Chiari; Davide Mei; Elena Parrini; Laura Grisotto; Carla Marini; Daniela Pucatti; Annarita Ferrari; Federico Sicca; Nicola Specchio; Marina Trivisano; Domenica Battaglia; Ilaria Contaldo; Nelia Zamponi; Cristina Petrelli; Tiziana Granata; Francesca Ragona; Giuliano Avanzini; Renzo Guerrini
Journal:  Neurology       Date:  2017-02-15       Impact factor: 9.910

Review 6.  Sodium channelopathies of skeletal muscle and brain.

Authors:  Massimo Mantegazza; Sandrine Cestèle; William A Catterall
Journal:  Physiol Rev       Date:  2021-03-26       Impact factor: 46.500

Review 7.  The genetic relationship between epilepsy and hemiplegic migraine.

Authors:  Yiqing Huang; Hai Xiao; Xingyue Qin; Yuan Nong; Donghua Zou; Yuan Wu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-24       Impact factor: 2.570

8.  Action potential initiation in neocortical inhibitory interneurons.

Authors:  Tun Li; Cuiping Tian; Paolo Scalmani; Carolina Frassoni; Massimo Mantegazza; Yonghong Wang; Mingpo Yang; Si Wu; Yousheng Shu
Journal:  PLoS Biol       Date:  2014-09-09       Impact factor: 8.029

9.  Genetic basis of pediatric epilepsy syndromes.

Authors:  Dongli Zhang; Xiaoming Liu; Xingqiang Deng
Journal:  Exp Ther Med       Date:  2017-03-27       Impact factor: 2.447

10.  Gain of Function for the SCN1A/hNav1.1-L1670W Mutation Responsible for Familial Hemiplegic Migraine.

Authors:  Sandra Dhifallah; Eric Lancaster; Shana Merrill; Nathalie Leroudier; Massimo Mantegazza; Sandrine Cestèle
Journal:  Front Mol Neurosci       Date:  2018-07-09       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.